Human Trials

Mereo BioPharma committee recommends continuation of BGS-649 study

Mereo BioPharma said that an independent data monitoring committee has recommended to continue all three different dose arms of the Phase 2b BGS-649 study after a prospectively defined interim analysis of safety and efficacy.

Chi-Med’s colorectal cancer drug shows positive results in phase 3 trial

Hutchison China MediTech has unveiled top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer (“CRC”) in China, who failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan

La Jolla’s blood pressure drug meets primary endpoint in phase 3 trial

La Jolla Pharmaceutical’s catecholamine resistant hypotension (CRH) drug, LJPC-501 (angiotensin II) has met its primary endpoint in a phase 3 study.

ProMetic’s pulmonary fibrosis drug yields positive results in phase 2 trial

ProMetic Life Sciences has revealed positive results for PBI-4050 from its open label Phase 2 clinical trial in idiopathic pulmonary fibrosis ("IPF") patients.

ImmusanT’s phase 1b trial of celiac disease vaccine finds phase 2 dose regimen

ImmusanT has completed a phase 1b clinical trial evaluating the safety and tolerability of Nexvax2 in celiac disease.

hVIVO says US body begins trial on malaria and Zika vaccine

Biopharmaceutical firm hVIVO PLC on Tuesday said the US National Institute of Health has initiated a phase one clinical trial of AGS-v, an investigational vaccine for mosquito-borne diseases like malaria and Zika.

ViiV Healthcare unveils positive study results for two-drug regimen for HIV

ViiV Healthcare has announced positive results from its phase 3 program assessing the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine.

Immunomedics, Seattle Genetics sign $2bn licensing deal for cancer drug

Immunomedics has signed a development and licensing agreement worth up to $2bn with Seattle Genetics for its experimental cancer drug.

Viking’s VK2809 demonstrates positive effect in POC study in glycogen storage disease

Preliminary results from a proof-of-concept (POC) study evaluating Viking Therapeutics' VK2809 in an in vivo model of a rare orphan disorder, dubbed glycogen storage disease Ia (GSD 1a), demonstrated an encouraging effect.